Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience
Mirjam G Wild,Felix Kreidel,Michaela M Hell,Fabien Praz,Markus Mach,Matti Adam,David Reineke,Hendrik Ruge,Sebastian Ludwig,Lenard Conradi,Tanja K Rudolph,Sabine Bleiziffer,Jörg Kellermair,Andreas Zierer,Georg Nickenig,Marcel Weber,Anna Sonia Petronio,Cristina Giannini,Gry Dahle,Kjell A Rein,Augustin Coisne,André Vincentelli,Christophe Dubois,Alison Duncan,Cesare Quarto,Axel Unbehaun,Ignacio Amat-Santos,Javier Cobiella,Nicolas Dumonteil,Rodrigo Estevez-Loureiro,Andrea Fumero,Tobias Geisler,Philipp Lurz,Antonio Mangieri,Vanessa Monivas,Thilo Noack,Luis Nombela Franco,Miguel A Pinon,Lukas Stolz,Didier Tchétché,Thomas Walter,Bernhard Unsöld,Stephan Baldus,Martin Andreas,Jörg Hausleiter,Ralph S von Bardeleben,TENDER Investigators
DOI: https://doi.org/10.1002/ejhf.2434
Abstract:Aims: Transcatheter mitral valve implantation (TMVI) is a new treatment option for patients with symptomatic mitral valve (MV) disease. Real-world data have not yet been reported. This study aimed to assess procedural and 30-day outcomes of TMVI in a real-world patient cohort. Method and results: All consecutive patients undergoing implantation of a transapically delivered self-expanding valve at 26 European centres from January 2020 to April 2021 were included in this retrospective observational registry. Among 108 surgical high-risk patients included (43% female, mean age 75 ± 7 years, mean STS-PROM 7.2 ± 5.3%), 25% was treated for an off-label indication (e.g. previous MV intervention or surgery, mitral stenosis, mitral annular calcification). Patients were highly symptomatic (New York Heart Association [NYHA] functional class III/IV in 86%) and mitral regurgitation (MR) was graded 3+/4+ in 95% (38% primary, 37% secondary, and 25% mixed aetiology). Technical success rate was 96%, and MR reduction to ≤1+ was achieved in all patients with successful implantation. There were two procedural deaths and 30-day all-cause mortality was 12%. At early clinical follow-up, MR reduction was sustained and there were significant reductions of pulmonary pressure (systolic pulmonary artery pressure 52 vs. 42 mmHg, p < 0.001), and tricuspid regurgitation severity (p = 0.013). Heart failure symptoms improved significantly (73% in NYHA class I/II, p < 0.001). Procedural success rate according to MVARC criteria was 80% and was not different in patients treated for an off-label indication (74% vs. 81% for off- vs. on-label, p = 0.41). Conclusion: In a real-world patient population, TMVI has a high technical and procedural success rate with efficient and durable MR reduction and symptomatic improvement.